Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD.
Azura Ophthalmics has raised €17M across 1 funding round from 4 investors, most recently a Series C round in Oct 2020. Based in Tel Aviv, Israel; founded 2014; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-10-26 | Series C |
| €17M |
| Ganot Capital,Medical Research Commercialisation Fund (MRCF),OrbiMed,TPG Biotech |
| View deal → |
